CompletedPhase 2NCT01700049
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
Studying Intraoral basal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Scott Fosko, MDfosko.scott@mayo.edu
- Intervention
- vismodegib (150 mg PO daily)(drug)
- Enrollment
- 28 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2018
Study locations (1)
- Saint Louis University Department of Dermatology, St Louis, Missouri, United States
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01700049 on ClinicalTrials.gov